二至天癸顆粒對lpd患者著床期子宮內(nèi)膜vegf影響研究

1、EffectsofErzhitianguiDecoctiononVEGFduringembryoimplantationoflutealphasedefectwomenSpeciality:GynecologyofTCMAuth:LiuXinyuanTut:Pof.LianFangAbstractObjective:toobservetheeffectofBushenherbsErzhitiangui(EZHTG)decoctionon

2、thefmationofendometriumbloodvesselsexpleitsactingmechanism.Methods:64patientsoflutealphasedefectwomenwereromlydividedintothetestgroup(EZHTGdecoctioncombinedwithwesternmedicine32cases)thecontrolgroup(Liuweidihuangdecoctio

3、ncombinedwithwesternmedicine32cases)whichgivenEZHTGdecoctionLiuweidihuangdecoctiontopretreatmentthreecycletime.AfterpretreatmentclomipenecombinedHMGweregivento2groupstoobservetheimprovementofsyndromeofTCMbefeaftertreatme

4、ntserumestradiolprogestonelevelbloodflowparametersoftheendometrialthebloodflowparametersofUterineartery(PI、RI)onthedayoflutealmetaphasebefeaftertreatmenttheexpressionofVEGFcomparedpregnancyrateaftertreatment.Results:1.th

5、etestgroupwasobviouslybetterthanthecontrolgroupinthesyndromepointsofKidneydeficiencybefeafterthetreatment(P＜005)2Afterthetreatmenttheserumestradiollevelonthedayoflutealmetaphaseofthetestgroupwerehigherthanthecontrolgroup

6、butthereisnosignificantdifference(P005)theserumprogestonelevelonthedayoflutealmetaphasethetestgroupwasobviouslyhigherthanthecontrolgroup(P005)theserumestradiolprogestonelevelonthedayoflutealmetaphasein2groupsthetestgroup

7、isobviouslysuperitothecontrolgroupcomparedwithbefetreatment(P005)3.AfterthetreatmentbloodflowparametersRIRIofendometrialonthedayoflutealmetaphaseofthetestgroupislowerthanthecontrolgroup（P＜005)thetestgroupisobviouslysuper

8、itothecontrolgroupcomparedwithbefetreatment（P＜001)4.AfterthetreatmentthebloodflowparametersofUterinearteryonthedayoflutealmetaphaseof目錄引言...................................................................................

9、............................................1臨床研究...............................................................................................................................21資料與方法.....................................

10、..................................................................................211病例來源......................................................................................................................212診斷標準......

11、................................................................................................................213病例選擇標準...................................................................................................

12、...........32研究方法............................................................................................................................421臨床病例分組......................................................................

13、........................................422材料與設備..................................................................................................................423方法和步驟..................................................

14、................................................................524免疫組化結果判斷......................................................................................................725觀察指標....................................

15、.................................................................................726統(tǒng)計方法......................................................................................................................73一般資料........

16、....................................................................................................................731兩組患者年齡比較.............................................................................................

17、.........732兩組患者不孕時間及流產(chǎn)次數(shù)比較..........................................................................833兩組患者治療前自然月經(jīng)周期第35天基礎內(nèi)分泌水平比較...............................834兩組患者治療前腎虛證候積分比較.........................................

18、.................................835兩組患者治療前黃體中期血清E2、P水平比較......................................................936兩組患者治療前黃體中期子宮內(nèi)膜血流PI、RI比較............................................937兩組患者治療前黃體中期子宮動脈血流PI、RI比較...........

19、..................................94研究結果............................................................................................................................941治療前后兩組患者中醫(yī)腎虛證候積分比較...................................

20、...........................942治療前后兩組患者黃體中期血清E2、P水平比較...............................................1043治療前后兩組患者黃體中期子宮內(nèi)膜血流PI、RI比較.......................................1044治療前后兩組患者黃體中期子宮動脈血流PI、RI比較........................